Deferiprone

Overview

Deferiprone is an oral iron chelator used to treat iron overload in patients with transfusion-dependent thalassemia. It forms a stable complex with trivalent iron (Fe3+) and is then eliminated from the body, reducing iron levels and preventing organ damage.

API suppliers (6)

Suppliers of Deferiprone backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• Apotex Inc.Canada1 active DMF
• Apotex Inc.Canada1 active DMF
• Emcure Pharmaceuticals LimitedIndia1 active DMF
• Emcure Pharmaceuticals LimitedIndia1 active DMF
• Emcure Pharmaceuticals LimitedIndia1 active DMF
• Cadila Healthcare LimitedIndia

Patent & exclusivity (US)

Per the FDA Orange Book (9 approved US products), the latest listed US patent on Deferiprone expires 24 Oct 2038 and exclusivity 29 Apr 2028. Generic API sourcing typically opens up once these lapse.

Therapeutic areas